Other Species / Isoforms
  JAK2 (mouse)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y119
ILYRIRFyFPHWYCS
Upstream
2 0
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) VLYRIRFyFPRWYCS Y119
JAK2 (mouse) ILYRIRFyFPHWYCS Y119
JAK2 (rat) ILYRIRFYFPHWYCS Y119
Y134
GSSRTYRyGVSRGAE
Upstream
1 1
Treatment
  • Epo
JAK2 (human) GSNRAYRHGISRGAE H134
JAK2 (mouse) GSSRTYRyGVSRGAE Y134
JAK2 (rat) GSNRTYRYGVSRGAE Y134
T174
KVPVTHETQEECLGM
1 1
JAK2 (human) KVPVTHEtQEECLGM T174
JAK2 (mouse) KVPVTHETQEECLGM T174
JAK2 (rat) KVPVTHETQEECLGM T174
Y201
DQTPLAVyNSVSyKT
Upstream
Downstream
3 1
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • JAK2 (mouse)
Treatment
  • angiotensin
  • Epo
JAK2 (human) DQTPLAIyNSISYKT Y201
JAK2 (mouse) DQTPLAVyNSVSyKT Y201
JAK2 (rat) DQTPLAVYNSISYKT Y201
Y206
AVyNSVSyKTFLPKC
Upstream
2 1
Kinase, in vitro:
  • JAK2 (mouse)
Treatment
  • Epo
JAK2 (human) AIyNSISYKTFLPKC Y206
JAK2 (mouse) AVyNSVSyKTFLPKC Y206
JAK2 (rat) AVYNSISYKTFLPKC Y206
Y221
VRAKIQDyHILTRKR
Upstream
Downstream
14 6
JAK2 (human)
Y221
JAK2 (mouse)
Y221
JAK2 (rat)
Y221
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Regulatory protein:
  • EPOR (human)
  • IRS1 (human)
  • IRS2 (human)
Treatment
  • AG490
  • apigenin
  • Epo
  • exercise training
  • GH
  • GM-CSF
  • IFN-gamma
  • PD98059
JAK2 (human) IRAKIQDyHILTRKR Y221
JAK2 (mouse) VRAKIQDyHILTRKR Y221
JAK2 (rat) VRAKIQDYHILTRKR Y221
Y317
TEQDVQLyCDFPDII
Upstream
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • Epo
  • IL-3
JAK2 (human) TEQDLQLYCDFPNII Y317
JAK2 (mouse) TEQDVQLyCDFPDII Y317
JAK2 (rat) TEQDLQLYCDFPDII Y317
Y372
FVSLIDGyyRLTADA
Upstream
Downstream
2 2
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
  • phosphorylation
  • protein stabilization
Effects on Biological Processes:
  • signaling pathway regulation
  • transcription, induced
Treatment
  • Epo
JAK2 (human) FVSLIDGYYRLTADA Y372
JAK2 (mouse) FVSLIDGyyRLTADA Y372
JAK2 (rat) FVSLIDGYYRLTADA Y372
Y373
VSLIDGyyRLTADAH
Downstream
1 1
Effects on Modified Protein
  • phosphorylation
JAK2 (human) VSLIDGYYRLTADAH Y373
JAK2 (mouse) VSLIDGyyRLTADAH Y373
JAK2 (rat) VSLIDGYYRLTADAH Y373
Y382
LTADAHHYLCKEVAP
0 1
JAK2 (human) LTADAHHyLCKEVAP Y382
JAK2 (mouse) LTADAHHYLCKEVAP Y382
JAK2 (rat) LTADAHHYLCKEVAP Y382
Y423
AGNQTGLyVLRCSPK
Upstream
1 3
Treatment
  • Epo
JAK2 (human) AGNQTGLyVLRCSPK Y423
JAK2 (mouse) AGNQTGLyVLRCSPK Y423
JAK2 (rat) AGNQTGLYVLRCSPK Y423
Y435
SPKDFNKyFLTFAVE
Upstream
1 4
Treatment
  • Epo
JAK2 (human) SPKDFNKyFLTFAVE Y435
JAK2 (mouse) SPKDFNKyFLTFAVE Y435
JAK2 (rat) SPKDFNKYFLTFAVE Y435
S518
VFRTNGISDVQIsPt
1 1
JAK2 (human) VFRTNGVsDVPtsPT S518
JAK2 (mouse) VFRTNGISDVQIsPt S518
JAK2 (rat) VFRTNGVSDVQLsPT S518
I522
NGISDVQIsPtLQRH
0 1
JAK2 (human) NGVsDVPtsPTLQRP T522
JAK2 (mouse) NGISDVQIsPtLQRH I522
JAK2 (rat) NGVSDVQLsPTLQRH L522
S523
GISDVQIsPtLQRHN
Upstream
Downstream
4 22
Effects on Modified Protein
  • enzymatic activity, inhibited
  • phosphorylation
Putative in vivo kinases:
  • ERK1 (human)
  • ERK2 (human)
Treatment
  • EGF
  • Epo
  • GH
  • IFN-gamma
  • IL-3
  • phorbol_ester
  • U0126
JAK2 (human) GVsDVPtsPTLQRPT S523
JAK2 (mouse) GISDVQIsPtLQRHN S523
JAK2 (rat) GVSDVQLsPTLQRHN S523
T525
SDVQIsPtLQRHNNV
0 1
JAK2 (human) sDVPtsPTLQRPTHM T525
JAK2 (mouse) SDVQIsPtLQRHNNV T525
JAK2 (rat) SDVQLsPTLQRHNNV T525
Y570
VRREVGDyGQLHKTE
Upstream
Downstream
8 862
Effects on Modified Protein
  • enzymatic activity, inhibited
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Regulatory protein:
  • EPOR (human)
  • FCER1A (mouse)
  • FLT3 (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) VRREVGDyGQLHETE Y570
JAK2 (mouse) VRREVGDyGQLHKTE Y570
JAK2 (rat) VRREVGDyGQLHETE Y570
Y613
HKHLVLNyGVCVCGE
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, induced
JAK2 (human) HKHLVLNYGVCVCGD Y613
JAK2 (mouse) HKHLVLNyGVCVCGE Y613
JAK2 (rat) HKHLVLNYGVCVCGE Y613
Y637
KFGSLDTyLKKNKNS
Upstream
Downstream
3 2
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • Epo
  • IL-3
JAK2 (human) KFGSLDTyLKKNKNC Y637
JAK2 (mouse) KFGSLDTyLKKNKNS Y637
JAK2 (rat) KFGSLDTYLKKNKNS Y637
S668
MHFLEEKsLIHGNVC
Upstream
1 1
Treatment
  • Epo
JAK2 (human) MHFLEENTLIHGNVC T668
JAK2 (mouse) MHFLEEKsLIHGNVC S668
JAK2 (rat) MHFLEEKSLIHGNVC S668
Y790
LINNCMDYEPDFRPA
0 1
JAK2 (human) LINNCMDyEPDFRPS Y790
JAK2 (mouse) LINNCMDYEPDFRPA Y790
JAK2 (rat) LINTCMDYEPDFRPA Y790
Y813
NSLFTPDyELLTEND
Upstream
Downstream
8 4
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • JAK2 (mouse)
Phosphatases, in vitro:
  • PTPRJ (human)
Putative upstream phosphatases:
  • PTPRJ (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) NSLFTPDyELLTEND Y813
JAK2 (mouse) NSLFTPDyELLTEND Y813
JAK2 (rat) NSLFTPDYELLTEND Y813
Y868
GSVEMCRyDPLQDNT
Upstream
Downstream
4 2
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Phosphatases, in vitro:
  • PTPRJ (human)
Putative in vivo kinases:
  • JAK2 (mouse)
Putative upstream phosphatases:
  • PTPRJ (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) GSVEMCRYDPLQDNT Y868
JAK2 (mouse) GSVEMCRyDPLQDNT Y868
JAK2 (rat) GSVEMCRYDPLQDNT Y868
S904
REIEILKsLQHDNIV
Upstream
1 7
Treatment
  • Epo
JAK2 (human) REIEILKsLQHDNIV S904
JAK2 (mouse) REIEILKsLQHDNIV S904
JAK2 (rat) REIEILKsLQHDNIV S904
Y913
QHDNIVKyKGVCySA
Upstream
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, inhibited
Effects on Biological Processes:
  • cell growth, altered
Kinase, in vitro:
  • JAK2 (mouse)
Regulatory protein:
  • EPOR (mouse)
Treatment
  • Epo
JAK2 (human) QHDNIVKYKGVCYSA Y913
JAK2 (mouse) QHDNIVKyKGVCySA Y913
JAK2 (rat) QHDNIVKYKGVCYSA Y913
Y918
VKyKGVCySAGRRNL
Upstream
1 0
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) VKYKGVCYSAGRRNL Y918
JAK2 (mouse) VKyKGVCySAGRRNL Y918
JAK2 (rat) VKYKGVCYSAGRRNL Y918
Y931
NLRLIMEyLPyGSLR
Upstream
1 6
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) NLKLIMEyLPyGsLR Y931
JAK2 (mouse) NLRLIMEyLPyGSLR Y931
JAK2 (rat) NLRLIMEYLPYGSLR Y931
Y934
LIMEyLPyGSLRDyL
Upstream
1 1
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) LIMEyLPyGsLRDyL Y934
JAK2 (mouse) LIMEyLPyGSLRDyL Y934
JAK2 (rat) LIMEYLPYGSLRDYL Y934
S936
MEyLPyGSLRDyLQK
0 1
JAK2 (human) MEyLPyGsLRDyLQK S936
JAK2 (mouse) MEyLPyGSLRDyLQK S936
JAK2 (rat) MEYLPYGSLRDYLQK S936
Y940
PyGSLRDyLQKHKER
Upstream
1 1
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) PyGsLRDyLQKHKER Y940
JAK2 (mouse) PyGSLRDyLQKHKER Y940
JAK2 (rat) PYGSLRDYLQKHKER Y940
Y956
DHKKLLQYTSQICKG
0 2
JAK2 (human) DHIKLLQyTSQICKG Y956
JAK2 (mouse) DHKKLLQYTSQICKG Y956
JAK2 (rat) DHKKLLQYTSQICKG Y956
Y966
QICKGMEyLGTKRyI
Upstream
Downstream
3 5
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) QICKGMEyLGTKRyI Y966
JAK2 (mouse) QICKGMEyLGTKRyI Y966
JAK2 (rat) QICKGMEYLGTKRYI Y966
Y972
EyLGTKRyIHRDLAT
Upstream
Downstream
3 1
Effects on Modified Protein
  • enzymatic activity, induced
  • phosphorylation
  • protein conformation
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • angiotensin_2
  • GH
JAK2 (human) EyLGTKRyIHRDLAT Y972
JAK2 (mouse) EyLGTKRyIHRDLAT Y972
JAK2 (rat) EYLGTKRYIHRDLAT Y972
Y1007
VLPQDKEyyKVKEPG
Upstream
Downstream
71 21
JAK2 (human)
Y1007
JAK2 (mouse)
Y1007
JAK2 (rat)
Y1007
Effects on Modified Protein
  • enzymatic activity, induced
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • cell growth, induced
  • signaling pathway regulation
Kinase, in vitro:
  • Abl (human)
  • BCR-ABL1 (human)
  • JAK2 (mouse)
Putative in vivo kinases:
  • BCR-ABL1 (human)
  • JAK2 (human)
Regulatory protein:
  • AR (mouse)
  • BCR-ABL1 (human)
  • CDC42 (human)
  • EPOR (mouse)
  • RHOA (human)
  • SH2-B-beta (mouse)
  • TLR3 (mouse)
Treatment
  • AG490
  • angiotensin_2
  • antibody
  • bacterial infection
  • CoCl2
  • EGF
  • Epo
  • GH
  • IL-3
  • IL-3_withdrawal
  • imatinib
  • isoproterenol
  • JAK2_inhibitor
  • JAK_inhibitor_I
  • leptin
  • mifepristone
  • MPA
  • MPTP
  • phenylephrine
  • PP2
  • TPO
JAK2 (human) VLPQDKEyyKVKEPG Y1007
JAK2 (mouse) VLPQDKEyyKVKEPG Y1007
JAK2 (rat) VLPQDKEyyKVKEPG Y1007
Y1008
LPQDKEyyKVKEPGE
Upstream
Downstream
68 19
JAK2 (human)
Y1008
JAK2 (mouse)
Y1008
JAK2 (rat)
Y1008
Effects on Modified Protein
  • enzymatic activity, induced
  • ubiquitination
Effects on Biological Processes:
  • cell growth, induced
  • signaling pathway regulation
Kinase, in vitro:
  • Abl (human)
  • BCR-ABL1 (human)
  • JAK2 (mouse)
Regulatory protein:
  • AR (mouse)
  • BCR-ABL1 (human)
  • CDC42 (human)
  • EPOR (mouse)
  • RHOA (human)
  • SH2-B-beta (mouse)
Treatment
  • AG490
  • angiotensin_2
  • antibody
  • CoCl2
  • EGF
  • Epo
  • GH
  • IL-3
  • IL-3_withdrawal
  • imatinib
  • isoproterenol
  • JAK_inhibitor_I
  • leptin
  • mifepristone
  • MPA
  • MPTP
  • phenylephrine
  • PP2
  • PQA-18
  • TPO
JAK2 (human) LPQDKEyyKVKEPGE Y1008
JAK2 (mouse) LPQDKEyyKVKEPGE Y1008
JAK2 (rat) LPQDKEyyKVKEPGE Y1008